2nd phase III study completed

RNS Number:4319I
Schering AG
07 March 2003



Second phase III study for Magnetic Resonance blood pool contrast agent MS-325
successfully completed

Berlin, March 7, 2003 - Schering AG, Berlin (FSE: SCH, NYSE: SHR) announced
today the results from the second Phase III clinical trial with MS-325 in
patients with suspected aortoiliac vascular disease. The positive results
demonstrate the potential efficacy and clinical utility of MS-325-enhanced
magnetic resonance angiography (MRA) in detecting vascular diseases. MS-325 is
developed by EPIX Medical (Nasdaq: EPIX) and Schering AG and is the first blood
pool MRI contrast agent for vascular imaging in the final stages of Phase III.
The clinical trial was conducted in patients around the world by EPIX. Schering
has exclusive worldwide sales and marketing rights to MS-325.

"We are pleased that the data from this clinical trial demonstrate the utility
of MS-325 enhanced MRA and look forward to providing a new clinical tool which
could have a significant impact in the diagnosis and management of vascular
diseases", said Michael Rook, Head of Diagnostics and Radiopharmaceuticals at
Schering AG, " With MS-325, we will continue to build on our market leadership
in MR contrast media".

Contrast enhanced MRA using MS-325 may reduce the frequency of invasive X-ray
angiography procedures, which can be associated with significant complications.
MS-325 offers the potential of accurate identification of arterial blockages and
abnormalities with a minimally-invasive method, while providing physicians with
a 3-D visualization of the vascular system without ionizing radiation.

About MS-325

MS-325 is a gadolinium-based MRI blood pool agent. It is the first MRI contrast
agent optimized for prolonged vascular enhancement. After intravenous injection,
MS-325 binds reversibly to human serum albumin in plasma thus providing an
extended imaging time window over currently available contrast agents. MS-325 is
designed to provide more flexibility and versatility including high resolution
scans in the clinical practice of MRA.

About the MS-325 Trial

In this second of four planned Phase III studies, patients with suspected
aortoiliac vascular disease received a 0.03 mmol/kg dose of MS-325.
MS-325-enhanced MRAs, non-contrast MRAs, and X-ray angiograms were obtained in
175 patients. The primary objectives of this trial were improvement in
sensitivity, specificity and accuracy for detection of clinical significant
stenosis for MS-325-enhanced MRA versus non-contrast MRA in comparison to the
Gold Standard X-ray angiography. Statistically significant improvement in
sensitivity, specificity and accuracy was demonstrated by three blinded readers.
Additionally the current data confirmed the results of the first Phase III
study.



Schering AG is a research-based pharmaceutical company. Its activities are
focused on four business areas: Gynecology&Andrology, Diagnostics&
Radiopharmaceuticals, Dermatology as well as Specialized Therapeutics for
disabling diseases in the fields of the central nervous system, oncology and
cardiovascular system. As a global player with innovative products Schering AG
aims for leading positions in specialized markets worldwide. With in-house R&D
and supported by an excellent global network of external partners, Schering AG
is securing a promising product pipeline. Using new ideas, Schering AG aims to
make a recognized contribution to medical progress and strives to improve the
quality of life: making medicine work

This press release has been published by Corporate Communication of Schering AG,
Berlin, Germany.

Your contacts at Corporate Communication:

Business: Oliver Renner, T: [phone]; [e-mail]

Investor Relations: Peter Vogt, T: [phone]; [e-mail]

Pharma: Dr Claudia Schmitt, T: [phone], [e-mail]

Your contacts in the US:

Media Relations: Kimberley Jordan, T:[phone],
[e-mail]

Investor Relations: Joanne Marion, T: [phone], [e-mail]



Find additional information at: www.schering.de/eng







Certain statements in this press release that are neither reported financial
results nor other historical information are forward-looking statements,
including but not limited to, statements that are predictions of or indicate
future events, trends, plans or objectives. Undue reliance should not be placed
on such statements because, by their nature, they are subject to known and
unknown risks and uncertainties and can be affected by other factors that could
cause actual results and Schering AG's plans and objectives to differ materially
from those expressed or implied in the forward-looking statements. Certain
factors that may cause such differences are discussed in our Form 20-F and Form
6-K reports filed with the U.S. Securities and Exchange Commission. Schering AG
undertakes no obligation to update publicly or revise any of these
forward-looking statements, whether to reflect new information or future events
or circumstances or otherwise.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

FURJRMLTMMIMMLJ